Sun Pharma's Billion-Dollar Leap: Acquisition of Organon

Sun Pharmaceutical Industries Ltd announced on Monday that it would acquire US-based Organon & Co in an all-cash deal valued at USD 11.75 billion. This acquisition will position Sun Pharma as a top player in women's health and biosimilars, expanding its global footprint.

In a major financial move, Sun Pharmaceutical Industries Ltd has declared its acquisition of US-based healthcare company Organon & Co in an all-cash deal worth USD 11.75 billion. This development led to a notable surge in Sun Pharma's shares, which rose over 7 percent on the stock markets.

The acquisition, priced at USD 14 per share, primes Sun Pharma not only to build on its current capabilities but also to emerge as a key player in the global healthcare landscape. The move is expected to enhance the company's standing particularly in the field of women's health and biosimilars.

Executive leaders from both companies expressed optimism about the merger. Sun Pharma's Executive Chairman, Dilip Shanghvi, highlighted the strategic fit and potential synergies, while Organon's Executive Chair, Carrie Cox, emphasized the compelling value offered to Organon's stakeholders through this transaction.